Cargando…
A Toxic Conformer of Aβ42 with a Turn at 22–23 is a Novel Therapeutic Target for Alzheimer’s Disease
Immunotherapy targeting Aβ42 is drawing attention as a possible therapeutic approach for Alzheimer’s disease (AD). Considering the significance of reported oligomerized Aβ42 species, selective targeting of the oligomer will increase the therapeutic efficacy. However, what kinds of oligomers are suit...
Autores principales: | Izuo, Naotaka, Kasahara, Chihiro, Murakami, Kazuma, Kume, Toshiaki, Maeda, Masahiro, Irie, Kazuhiro, Yokote, Koutaro, Shimizu, Takahiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603611/ https://www.ncbi.nlm.nih.gov/pubmed/28924167 http://dx.doi.org/10.1038/s41598-017-11671-6 |
Ejemplares similares
-
Monoclonal antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the Alzheimer’s disease diagnosis
por: Murakami, Kazuma, et al.
Publicado: (2016) -
Detection of Amyloid β Oligomers with RNA Aptamers
in App(NL-G-F/NL-G-F) Mice: A
Model of Arctic Alzheimer’s Disease
por: Obata, Yayoi, et al.
Publicado: (2020) -
Formation of the 42-mer Amyloid β
Radical and the Therapeutic Role of Superoxide Dismutase in Alzheimer's Disease
por: Murakami, Kazuma, et al.
Publicado: (2011) -
Lysine-targeting inhibition of amyloid β oligomerization by a green perilla-derived metastable chalcone in vitro and in vivo
por: Murakami, Kazuma, et al.
Publicado: (2022) -
Superoxide Dismutase 1 Loss Disturbs Intracellular Redox Signaling, Resulting in Global Age-Related Pathological Changes
por: Watanabe, Kenji, et al.
Publicado: (2014)